Clinical trials: Metastatic Renal Cell Carcinoma (mRCC)
Renal Cell Carcinoma (RCC)
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell…
- Trial name
- NCT03260894
- Testing
- Pembrolizumab, Epacadostat, Sunitinib
- Where
- 140 sites in United States, Australia and 18 more
- Volunteers
- 129 people
- Sponsor
- Incyte Corporation
Kidney Cancer, Renal Cell Carcinoma
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
To assess whether changes in quantitative tumor perfusion parameters after 3 or 6 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to…
- Conditions
- Kidney Cancer, Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Trial name
- NCT04508725
- Testing
- Doppler Ultrasound, SIEMENS S3000 and Verasonics Vantage 256, Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Diarrhea, Metastatic Renal Cell Carcinoma
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor
This randomized clinical trial studies how well probiotic yogurt supplement works in reducing diarrhea in patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) and that are…
- Conditions
- Diarrhea, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Trial name
- NCT02944617
- Testing
- Laboratory Biomarker Analysis, Micronutrient-Fortified Probiotic Yogurt, VEGF-TKI
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- City of Hope Medical Center
Carcinoma, Renal Cell
"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
Retrospective study to collect data from Patients with advanced/metastatic renal cell carcinoma previously treated with Axitinib under standard clinical practice, to describe the clinical profile of the patients with a long…
- Trial name
- NCT03538717
- Where
- 40 sites in Spain
- Volunteers
- 157 people
- Sponsor
- Pfizer
Metastatic Clear Cell Renal Cell Carcinoma
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide…
- Trial name
- NCT01896271
- Testing
- IL-2, Stereotactic Ablative Body Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Renal Cell Carcinoma
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
The purpose of this study is to assess the safety and efficacy of monotherapy pembrolizumab (MK-3475) in participants with renal cell carcinoma (RCC).
- Trial name
- NCT02853344
- Testing
- Pembrolizumab
- Volunteers
- 275 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Renal Cell Carcinoma
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients with metastatic renal cell cancer.
- Trial name
- NCT01223027
- Testing
- Dovitinib, Sorafenib
- Where
- 199 sites in United States, Argentina and 25 more
- Volunteers
- 564 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Cancer
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's lymphocytes to kill kidney cancer cells.
- Trial name
- NCT00085436
- Testing
- Aldesleukin,, autologous tumor cell vaccine, recombinant interferon alfa
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Metastatic Renal Cell Carcinoma
Sutent Rechallenge In mRCC Patients
Retrospective and prospective study in mRCC patients treated with sutent in first line and rechallenged by Sutent in 3rd and 4th line.
- Trial name
- RESUME (NCT01827254)
- Testing
- sunitinib: observational study
- Where
- 18 sites in France
- Volunteers
- 61 people
- Sponsor
- Pfizer
Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
This phase II trial studies how well pazopanib hydrochloride works in treating patients with kidney cancer that has spread to other places in the body (metastatic).
- Conditions
- Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma, Kidney Medullary Carcinoma, Kidney Oncocytoma
- Trial name
- NCT01767636
- Testing
- Pazopanib Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Carcinoma, Renal Cell
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
To investigate objective tumor response of AG-013736 for metastatic Renal Cell Cancer (mRCC)
- Trial name
- NCT00569946
- Testing
- AG-013736
- Where
- 18 sites in Japan
- Volunteers
- 64 people
- Sponsor
- Pfizer
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works in treating patients…
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01157091
- Testing
- pazopanib hydrochloride, laboratory biomarker analysis, immunologic technique
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- City of Hope Medical Center
Renal Cell Carcinoma, Metastatic
Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
The purpose of this study is to compare tumor response, progression free survival (PFS) and overall survival (OS) in newly diagnosed mRCC patients treated with Intuvax (INN: ilixadencel) pre-nephrectomy followed by Sunitinib…
- Trial name
- MERECA (NCT02432846)
- Testing
- Intuvax (INN: ilixadencel), Sunitinib
- Where
- 28 sites in United States, Czechia and 7 more
- Volunteers
- 88 people
- Sponsor
- Mendus
Metastatic Renal Cell Carcinoma, RCC
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
This is a Phase I/II trial of the combination pegylated IFN-alpha 2b with ixazomib in metastatic renal cell carcinoma (mRCC). Researchers believe that by disabling the protein complex NF-kB, which controls the transfer of genetic…
- Trial name
- NCT02447887
- Testing
- Ixazomib, Pegylated IFN-alpha 2b
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Metastatic Renal Cell Carcinoma ( mRCC)
A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)
To describe real-world demographic and clinical characteristics, treatment characteristics, and clinical outcomes among patients in Latin America who were treated with first-line sunitinib for metastatic renal cell carcinoma and…
- Trial name
- NCT04115189
- Testing
- Sunitinib
- Where
- 7 sites in Argentina, Brazil and 2 more
- Volunteers
- 57 people
- Sponsor
- Pfizer
Metastatic Renal Cell Carcinoma (mRCC)
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
The study aims to assess clinical outcomes in mRCC patients treated with sunitinib in second-line following IO therapy in real world clinical practices.
- Trial name
- NCT04175262
- Testing
- sunitinib
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for participants with advanced/metastatic renal cell…
- Trial name
- NCT02853331
- Testing
- Pembrolizumab, Axitinib, Sunitinib
- Volunteers
- 861 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Renal Cell Carcinoma
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
This is a retrospective, longitudinal cohort study that assessed clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib as first-line treatment.
- Trial name
- NCT04076787
- Testing
- Sunitinib
- Where
- Canada
- Volunteers
- 1,769 people
- Sponsor
- Pfizer
Renal Cell Carcinoma, Neoplasm Metastases
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
The purpose of this research study is to determine if the combination of sunitinib and gemcitabine is effective in treating patients with metastatic renal cell carcinoma. The safety of this combination will also be studied.
- Trial name
- NCT00556049
- Testing
- Gemcitabine, Sunitinib
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
Genitourinary Cancer, Kidney Cancer
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
The goal of this clinical research study is to learn more about the safety of giving sunitinib to patients with metastatic kidney cancer for 2 weeks followed by 1 week in which they receive no drug.
- Trial name
- NCT02060370
- Testing
- Sunitinib, Questionnaire
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center